Open AccessRadium‐223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration‐Refractory Prostate Cancer: Final Safety and Efficacy Results
Author(s) -
Maughan Benjamin L.,
Kessel Adam,
McFarland Taylor Ryan,
Sayegh Nicolas,
Nussenzveig Roberto,
Hahn Andrew W.,
Hoffman John M.,
Morton Kathyrn,
Sirohi Deepika,
Kohli Manish,
Swami Umang,
Boucher Kenneth,
Haaland Benjamin,
Agarwal Neeraj
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13949
Subject(s) - enzalutamide , medicine , prostate cancer , oncology , adverse effect , progression free survival , urology , cancer , overall survival , androgen receptor
Long-term safety of radium-223 with enzalutamide was confirmed in this clinical trial. PSA-PFS2 was prolonged with the combination compared with enzalutamide alone.